Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications
Riham Ayoubi, Joël Ryan, Michael Biddle…·Carl Laflamme
Over half of 614 commercial antibodies for 65 human neuroscience proteins failed a knockout-controlled assay, yet most targets had a well-performing antibody; recombinants performed best.